Form 8-K - Current report:
SEC Accession No. 0000926617-20-000024
Filing Date
2020-05-07
Accepted
2020-05-07 17:19:47
Documents
5
Period of Report
2020-05-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vrml-20200507x8k.htm 8-K 45199
2 EX-10.1 vrml-20200507xex10_1.htm EX-10.1 9647
3 GRAPHIC vrml-20200507xex10_1g001.jpg GRAPHIC 181106
4 GRAPHIC vrml-20200507xex10_1g002.jpg GRAPHIC 184765
5 GRAPHIC vrml-20200507xex10_1g003.jpg GRAPHIC 90889
  Complete submission text file 0000926617-20-000024.txt   685899
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
VERMILLION, INC. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 20857676
SIC: 2835 In Vitro & In Vivo Diagnostic Substances